Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Emoxypine is a synthetic antioxidant and nootropic drug with a 3-hydroxypyridine structure similar to Vitamin B6 (pyridoxine). Its mechanism of action includes antioxidant and membranotropic effects, modulation of receptor functioning and membrane-bound enzymes, and restoration of neurotransmitter balance. Emoxypine exhibits a wide range of pharmacological effects at both neuronal and vascular levels, including antihypoxic, anti-ischemic, neuroprotective, nootropic, anxiolytic, anticonvulsant, cardioprotective, and anti-atherogenic properties. It improves cerebral circulation and microcirculation, and has the ability to cross the blood-brain barrier due to its small size and low molecular weight. Emoxypine has shown iron chelating properties in vitro, suggesting potential therapeutic applications in neurodegenerative conditions like Alzheimer's disease and hematologic disorders such as thalassemia and hemochromatosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on emoxypine.